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Abstract 
Background 
The prevalence of chronic kidney disease (CKD) increases with age, and new glomerular 
filtration rate-estimating equations have recently been validated. The epidemiology of CKD 
in older individuals and the relationship between a low estimated glomerular filtration rate as 
calculated by these equations and adverse outcomes remains unknown. 
Methods 
Data from the BELFRAIL study, a prospective, population-based cohort study of 539 
individuals aged 80 years and older, were used. For every participant, five equations were 
used to calculate estimated glomerular filtration rate based on serum creatinine and/or 
cystatin C values: MDRD, CKD-EPIcreat, CKD-EPIcyst, CKD-EPIcreatcyst, and BIS 
equations. The outcomes analyzed included mortality combined with the necessity of new 
renal replacement therapy, severe cardiovascular events, and hospitalization. 
Results 
During the follow-up period, which was an average of 2.9 years, 124 participants died, 7 
required renal replacement therapy, 271 were hospitalized, and 73 had a severe 
cardiovascular event. The prevalence of estimated glomerular filtration rate values <60 
mL/min/1.73 m2 differed depending on the equation used as follows: 44% (MDRD), 45% 
(CKD-EPIcreat), 75% (CKD-EPIcyst), 65% (CKD-EPIcreatcyst), and 80% (BIS). All of the 
glomerular filtration rate-estimating equations revealed that higher cardiovascular mortality 
was associated with lower estimated glomerular filtration rates and that higher probabilities 
of hospitalization were associated with estimated glomerular filtration rates <30 mL/min/1.73 
m
2
. A lower estimated glomerular filtration rate did not predict a higher probability of severe 
cardiovascular events, except when using the CKD-EPIcyst equation. By calculating the net 
reclassification improvement, CKD-EPIcyst and CKD-EPIcreatcyst were shown to predict 
mortality (+25% and +18%) and severe cardiovascular events (+7% and +9%) with the 
highest accuracy. The BIS equation was less accurate in predicting mortality (-12%). 
Conclusion 
Higher prevalence of CKD were found using the CKD-EPIcyst, CKD-EPIcreatcyst, and BIS 
equations compared with the MDRD and CKD-EPIcreat equations. The new CKD-
EPIcreatcyst and CKD-EPIcyst equations appear to be better predictors of mortality and 
severe cardiovascular events. 
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Background 
Chronic kidney disease (CKD) is an important public health problem. First, dialysis and 
kidney transplantation impose a high cost on society. The cost of dialysis per patient per year 
in Belgium is more than 50,000 Euros, and >1% of the health budget of the Belgian 
government is used to cover dialysis costs. Second, patients with CKD have a high risk for 
cardiovascular events and mortality [1,2]. Therefore, many therapeutic and diagnostic drugs 
cannot be used or, if used, require dosing adaptation prior to use in patients with CKD. 
The prevalence of CKD, when defined as an estimated glomerular filtration rate (eGFR) <60 
mL/min/1.73 m2, increases with age. In Western countries [3,4], prevalence is approximately 
10% at the age of 65 years and increases to 60% in individuals aged 80 years and older. The 
best method for estimating the GFR in older individuals remains unclear. Until recently, only 
limited validation of the equations used to estimate GFR in older individuals has been 
performed [5]. 
In 2012, three new GFR-estimating equations based on serum creatinine and serum cystatin C 
values, age, and gender were validated. Two of the studies were based on data from the 
CKD-EPI consortium [6] (with only limited numbers of older persons), and one was based on 
data from the Berlin Initiative Study (with only persons aged 70 and older) [7]. However, the 
epidemiology of CKD in older individuals and the relationship between low eGFR and 
adverse outcomes determined using these new equations have not been investigated. 
In this study, we used the data from the BELFRAIL study to analyze the ability of GFR, 
estimated by older equations like the MDRD and CKD-EPI creatinine equations and the three 
new GFR equations, to predict mortality, necessity of renal replacement therapy (RRT), 
hospitalization, and severe cardiovascular events. 
Methods 
Study design 
The BELFRAIL study is a prospective, observational, population-based cohort study of 
individuals aged 80 years and older in three well-circumscribed areas in Belgium. The study 
design and the characteristics of the cohort have previously been described in detail [8]. 
Briefly, 29 general practitioner (GP) centers were asked to recruit consecutive patients aged 
80 years and older. Only three exclusion criteria were used: the presence of severe dementia, 
the necessity of palliative care, and medical urgency. The study protocol was approved by the 
Biomedical Ethics Committee of the Université Catholique de Louvain Medical School in 
Belgium (B40320084685), and all of the study participants provided informed consent. 
The participants were recruited to the BELFRAIL study between 2 November 2008 and 15 
September 15 2009. The GPs recorded the patients’ age, gender, and detailed medical history. 
The follow-up data regarding severe events in these participants were collected by 
questioning each participant’s GP 18 and 36 months after inclusion and baseline data 
collection. During this questioning, the following outcome parameters were collected: the 
exact date and cause of the total and cardiovascular mortality, severe cardiovascular events, 
necessity of RRT, and the date of and reason for hospitalizations. 
Laboratory tests 
All blood samples were collected in the morning, and all measurements were performed in 
the laboratories of the Cliniques Universitaires St. Luc, Brussels. The serum concentration of 
creatinine was measured in the baseline blood sample using a UniCel DxC 800 Synchron 
instrument (Beckman Coulter, Inc., Brea, CA, USA). The creatinine assay was based on the 
Jaffé compensated isotope dilution mass spectrometry method, with total coefficient of 
variation ranging from 1.6% to 2% (105 to 1,049 µmol/L) in serum [9]. The N-latex cystatin 
C assay was based on an immunonephelometric method performed using the BNII analyzer 
from Siemens Diagnostics (Erlangen, Germany). The assay displayed total coefficient of 
variation from 2.3% to 4.3% (0.8 to 7.1 mg/L). The assay was run according to the 
manufacturer’s instructions and standards provided and met the new cystatin C International 
Federation of Clinical Chemistry and Laboratory Medicine standardization [10]. 
Main parameters 
Previously diagnosed hypertension, diabetes, myocardial infarction, cerebrovascular accident, 
and peripheral arterial disease, as well as past and current smoking history, were ascertained 
by each participant’s physician based on the medical files of the participant. 
Five different equations were used to estimate the GFR, outlined below. 
The isotope dilution mass spectrometry traceable MDRD equation (MDRD) [11]: 
( ) ( ) ( ) ( )1.154 0.203175 0.742 1.212aGFR S Age if female if black− −= × × × ×
   
The Chronic Kidney Disease Epidemiology Collaboration equation [12] using creatinine 
(CKD-EPIcreat): 
( ) ( ) ( ) ( )1,209141 , , 0.993 1.018 1.159a Agea aGFR min S k l max S k l if female if black−= × × × × ×
  
The Chronic Kidney Disease Epidemiology Collaboration cystatin C equation (CKD-
EPIcyst) [6]: 
( ) ( ) [ ]0.499 1.328133 0.8 0.8 0.996 0.932AgeGFR min Scys max Scys if female− −= × × × ×
  
The Chronic Kidney Disease Epidemiology Collaboration creatinine and cystatin C equation 
(CKD-EPIcreatcyst) [6]: 
( ) ( ) ( ) ( ) [ ][ ]0.601 .375 0.711135 , , 0.8,1 0.8,1 0.995 0.969 1.08a ageGFR min Scr k l max Scr k l min Scys max Scys if female if black− − − −= × × × × × × ×
 
The Berlin Initiative Study Equation 2 (BIS) [7]: 
[ ]0.61 0.40 0.57767 0.87GFR Scys Scr age if female− −= × × × ×
  
 
The participants were classified into five categories based on their eGFR as follows: >90, 60 
to 90, 45 to 60, 30 to 45, and <30 mL/min/1.73 m2. 
Statistical methods 
Baseline differences between the groups with different eGFR values were assessed using the 
chi-square test for categorical parameters and one-way analysis of variance for normally 
distributed variables. 
A Cox proportional hazards model was used to study the risk associated with the various 
CKD categories based on the different GFR-estimating equations for ‘renal death’ (defined as 
mortality or the necessity of RRT), cardiovascular mortality, severe cardiovascular events, 
and hospitalization. Two models were used. The first model (model 1) was adjusted for age 
and gender, and the second model (model 2) was adjusted for known risk factors (age, 
gender, hypertension, diabetes mellitus, history of a serious cardiovascular event, and 
smoking status). The odds ratios (ORs) for having no events (mortality, necessity of RRT, 
severe cardiovascular event, or hospitalization) during the follow-up period were estimated 
using logistic regression. The same models (models 1 and 2) were used to make adjustments. 
All of these analyses were performed using SPSS version 19. 
The net reclassification improvement (NRI) [13], which was compared with the GFR 
estimated by the MDRD equation, was calculated with the other equations for the different 
outcomes and using a cutoff value of 60 mL/min/1.73 m2. 
Results 
All of the necessary baseline data were available for all of the GFR calculations in 539 of the 
567 participants in the BELFRAIL study. None of these 539 persons were lost to follow-up. 
The mean follow-up period from the baseline blood collection was 2.9 ±0.3 years. During 
this period, 124 of the participants died and 7 required RRT. Furthermore, 271 participants 
were hospitalized at least once, and 73 had at least one severe cardiovascular event. Table 1 
lists the general characteristics of the population and the differences in these characteristics 
for participants with an eGFR >60 and <60 mL/min. 
Table 1 General characteristics of the BELFRAIL population at baseline (n = 539), based on 
eGFR values at study entry, as estimated by different equations 
 All MDRD <60 
mL/min 
CKD-EPIcreat 
<60 mL/min 
CKD-EPIcyst <60 
mL/min 
CKD-
EPIcreatcyst 
<60 mL/min 
BIS <60 mL/min 
(n = 539) (n = 237, 44%) (n = 244, 45%) (n = 405, 75%) (n = 247, 46%) (n = 431, 80%) 
Mean age 84.7 85.6a 85.7a 85.0a 84.7 84.7 
(SD 3.6) (SD 4.0) (SD 4.0) (SD 3.8) (SD 3.7) (SD 3.7) 
Male gender (%) 37 37 35 40 37 37 
Hypertension (%) 70 73 79a 73 71 73 
Diabetes mellitus (%) 19 20 21 19 19 20 
History of myocardial infusion (%) 11 13 12 13 11 13 
History of cerebrovascular accident (%) 8 9 8 9 9 9 
History of peripheral arterial disease (%) 9 9 12 10 9 9 
Smoker (%) 3 3 3 3 3 4 
a
 P <0.05 compared with the subgroup of participants with eGFR >60 mL/min/1.73 m2. SD, standard 
deviation. 
For the entire study population, the mean eGFR determined was 64 ±22 mL/min using the 
MDRD equation, 61 ±19 mL/min using the CKD-EPIcreat equation, 49 ±21 mL/min using 
the CKD-EPIcyst equation, 54 ±27 mL/min using the CKD-EPIcreatcyst equation, and 48 
±15 mL/min using the BIS equation. The prevalence of CKD defined as eGFR <60 mL/min 
differed based on the equation used and was as follows: 44% (MDRD), 45% (CKD-
EPIcreat), 75% (CKD-EPIcyst), 65% (CKD-EPIcreatcyst), and 80% (BIS). The prevalence of 
severe CKD, defined as eGFR <30 mL/min, also differed as follows: 6% (MDRD), 7% 
(CKD-EPIcreat), 20% (CKD-EPIcyst), 13% (CKD-EPIcreatcyst), and 10% (BIS). 
Table 2 shows the relationship between CKD stage and renal death (defined as mortality or 
the necessity of RRT), with participants with an eGFR of 60 to 90 mL/min as the reference 
group. The results are shown as hazard ratios (HRs) adjusted using two models with different 
confounders: age and gender; and age, gender, hypertension, diabetes mellitus, history of a 
serious cardiovascular event and smoking status. The absolute number of renal deaths was 43 
(18%) in the MDRD reference group, 46 (16%) in the CKD-EPIcreat reference group, 13 
(13%) in the CKD-EPIcyst reference group, 22 (14%) in the CKD-EPIcreatcyst reference 
group, and 13 (13%) in the BIS reference group. 
Table 2 Relationship between estimated glomerular filtration rate and death or the 
necessity of renal replacement therapy 
  Estimated glomerular filtration rate (mL/min)  
  >90 60 to 90 45 to 60 30 to 45 <30 P 
MDRD events 8/72 43/232 34/129 30/76 16/30  
 HR1 0.60 1 1.44 2.12 3.34 0.000 
(0.28 to 1.28) (0.90 to 2.29) (1.30 to 3.45) (1.87 to 5.99) 
 HR2 0.60 1 1.35 2.03 3.32 0.000 
(0.28 to 1.28) (0.85 to 2.15) (1.25 to 3.30) (1.82 to 6.05) 
CKD-EPIcreat events 3/9 46/288 35/126 24/78 23/38  
 HR1 2.76 1 1.77 1.83 4.89 0.000 
(0.84 to 9.01) (1.12 to 2.78) (1.09 to 3.05) (2.93 to 8.17) 
 HR2 3.01 1 1.65 1.72 5.04 0.000 
(0.91 to 9.96) (1.05 to 2.61) (1.03 to 2.88) (2.95 to 8.60) 
CKD-EPIcyst events 4/36 13/97 29/152 32/148 53/106  
 HR1 0.81 1 1.29 1.44 3.49 0.000 
(0.27 to 2.50) (0.67 to 2.50) (0.75 to 2.75) (1.87 to 6.50) 
 HR2 0.76 1 1.19 1.43 3.41 0.000 
(0.25 to 2.36) (0.61 to 2.32) (0.75 to 2.75) (1.81 to 6.42) 
CKD-EPIcreatcyst events 6/37 22/154 30/157 34/123 39/68  
 HR1 1.23 1 1.34 1.82 4.14 0.000 
(0.49 to 3.04) (0.77 to 2.35) (1.05 to 3.17) (2.39 to 7.15) 
 HR2 1.14 1 1.30 1.76 4.29 0.000 
(0.46 to 2.88) (0.74 to 2.30) (1.01 to 3.09) (2.41 to 7.63) 
BIS event/total 2/4 13/104 36/215 45/160 35/56  
 HR1 4.63 1 1.26 2.01 5.09 0.000 
(1.04 to 20.57) (0.67 to 2.39) (1.08 to 3.77) (2.66 to 9.76) 
 HR2 4.75 1 1.31 1.98 5.58 0.000 
(1.06 to 21.25) (0.69 to 2.50) (1.05 to 2.50) (2.84 to 10.96) 
HR1, Hazard ratio for model 1 - adjusted for age and gender; HR2, Hazard ratio for model 2 - 
adjusted for age, gender, hypertension, diabetes mellitus, history of a serious cardiovascular 
event and smoking status. 
Significantly higher cardiovascular mortality was observed when the eGFR decreased in all 
five of the GFR-estimating equations (Figure 1A). By contrast (see Figure 1B), a lower eGFR 
did not predict a higher probability of severe cardiovascular events, except when the GFR 
was estimated by the CKD-EPIcyst equation. The relationship between the CKD-EPIcyst 
GFR and severe cardiovascular events appeared to be U-shaped, with more events occurring 
at higher eGFR values (eGFR >90 mL/min; adjusted HR of 3.85; 95% confidence interval 
(CI) 1.28, 11.64) and lower eGFR values (eGFR <30 mL/min; adjusted HR of 3.06; 95% CI 
1.19, 7.90). 
Figure 1 Cardiovascular mortality (1A) and severe cardiovascular events (1A) 
depending on the eGFR value estimated by different expressed as hazard ratios (HR) 
Values greater than 1.0 indicate an increased risk. 
Analysis of the interval to first hospitalization as a function of eGFR-based CKD stage 
(Figure 2) revealed that participants with an eGFR <30 mL/min had a higher risk for 
hospitalization, regardless of the GFR estimation equation used. Table 3 presents the 
probability of experiencing no events, as analyzed by linear regression analysis. The 
subgroup with an eGFR <30 mL/min had a higher risk of an event in all of the GFR 
estimations. All of the participants with an estimated GFR <60 mL/min based on the CKD-
EPI had a higher risk of an event. 
Figure 2 Hospitalizations depending on the eGFR value estimated by different 
expressed as hazard ratios (HR) Values greater than 1.0 indicate an increased risk. 
Table 3 Relationship between having no events during the 2.9-year follow-up period and 
the estimated glomerular filtration categories derived from logistic regression 
  Estimated glomerular filtration rate (mL/min)  
  >90 60 to 90 45 to 60 30 to 45 <30 P 
MDRD events 38/72 110/232 49/129 22/76 6/30  
OR1 1.17 1 0.76 0.55 0.32 0.003 
(0.69 to 1.99) (0.49 to 1.19) (0.31 to 0.98) (0.13 to 0.83) 
OR2 1.11 1 0.82 0.58 0.33 0.022 
(0.64 to 1.93) (0.52 to 1.30) (0.33 to 1.04) (0.13 to 0.87) 
CKD-EPIcreat event 4/9 143/288 45/126 27/78 6/38  
OR1 0.73 1 0.64 0.65 0.23 0.02 
(0.19 to 2.82) (0.41 to 1.00) (0.38 to 1.12) (0.09 to 0.56) 
OR2 0.64 1 0.69 0.70 0.24 0.033 
(0.16 to 2.48) (0.44 to 1.09) (0.40 to 1.21) (0.09 to 0.60) 
CKD-EPIcyst event 20/36 54/97 65/152 60/148 26/106  
OR1 1.00 1 0.59 0.56 0.31 0.000 
(0.46 to 2.17) (0.35 to 0.99) (0.33 to 0.95) (0.17 to 0.58) 
OR2 1.00 1 0.56 0.56 0.34 0.03 
(0.45 to 2.24) (0.33 to 0.97) (0.33 to 0.96) (0.18 to 0.63) 
CKD-EPIcreatcyst event 21/37 79/154 70/157 42/123 13/68  
OR1 1.26 1 0.81 0.57 0.29 0.000 
(0.61 to 2.26) (0.51 to 1.27) (0.35 to 0.95) (0.14 to 0.57) 
OR2 1.41 1 0.83 0.63 0.32 0.03 
(0.66 to 3.00) (0.52 to 1.32) (0.38 to 1.06) (0.15 to 0.65) 
BIS event 2/4 54/104 103/215 55/160 11/56  
 OR1 1.02 1 0.90 0.59 0.30 0.002 
(0.14 to 7.64) (0.56 to 1.44) (0.35 to 0.80) (0.14 to 0.64) 
 OR2 1.00 1 0.92 0.66 0.32 0.01 
(0.13 to 7.82) (0.56 to 1.50) (0.38 to 1.13) (0.14 to 0.71) 
An event was defined as mortality, the necessity of renal replacement therapy, a serious 
cardiovascular event or hospitalization. OR1, Odds ratio adjusted for age and gender; OR2, odds 
ratio adjusted for age, gender, hypertension, diabetes mellitus, history of a serious 
cardiovascular event and smoking status. 
With regard to absolute numbers, the CKD-EPIcys, CKD-EPIcreatcyst and BIS2 equations 
classified most of the participants who died in the subgroup with eGFR <60 mL/min at 
baseline (Table 2), but they only classified 33% (CKD-EPIcyst), 44% (CKD-EPIcreatcyst) 
and 25% (BIS) of the individuals experiencing no events in the group with eGFR >60 
mL/min (see Table 3). The MDRD and CKD-EPIcreat equations not only predicted a higher 
absolute number of renal deaths in the group with eGFR >60 mL/min at baseline (see Table 
2) but also higher numbers of renal deaths (66% with MDRD and 65% with CKD-EPI) in the 
group with eGFR <60 mL/min (Table 3). 
The differences in the ability of the different GFR-estimating equations to predict adverse 
outcomes were further analyzed by measuring the NRI determined using the MDRD 
equation, using a cutoff value of 60 mL/min/1.73 m2. This NRI is reported in Table 4. The 
CKD-EPIcreat equation exhibited limited differences from the MDRD equation, and the BIS 
equation was less accurate than the MDRD equation in the prediction of renal death. 
Table 4 The net reclassification improvement generated by employing different 
formulas using MDRD as a reference and a cutoff value of 60 mL/min/1.73 m2 
Equation used Outcome NRI using a 60 mL/min cutoff P 
CKD-EPIcreat Renal death 2% 0.08 
Cardiovascular events 0% 0.49 
Hospitalization 1% 0.13 
No events −2% 0.05 
CKD-EPIcyst Renal death 25% <0.01 
Cardiovascular events 7% 0.04 
Hospitalization 3% 0.30 
No events 1% 0.45 
CKD-EPIcreatcyst Renal death 18% <0.01 
Cardiovascular events 9% 0.03 
Hospitalization −2% 0.36 
No events 0% 0.49 
BIS Renal death −12% 0.01 
Cardiovascular events −2% 0.43 
Hospitalization −7% 0.07 
No events −7% 0.09 
Renal death (mortality or renal replacement therapy), severe cardiovascular events, 
hospitalization or absence of events over a three-year period were used as outcomes. NRI, net 
reclassification improvement. 
Discussion 
Key findings 
When using different equations to estimate the GFR, we found large differences (between 
40% and 80%) in the prevalence of CKD (eGFR <60 mL/min) and large differences (between 
6% and 20%) in the prevalence of severe CKD (eGFR <45 mL/min). Despite these 
differences in prevalence and regardless of the equation used, participants with an eGFR <30 
mL/min were at extremely high risk for mortality, cardiovascular mortality and 
hospitalization. No relationship between eGFR and non-fatal cardiovascular events was 
found, except when the GFR was determined using the CKD-EPIcyst equation, which 
revealed a U-shaped relationship between eGFR and cardiovascular events. The MDRD and 
CKD-EPIcreat equations not only classified most of the participants with no events in the 
eGFR >60 mL/min group, but also higher numbers of participants with renal death in the 
same subgroup. The CKD-EPIcyst, CKD-EPIcreatcyst and BIS equations demonstrated the 
opposite pattern, identifying fewer renal deaths and classifying fewer numbers of participants 
with no events in the >60 mL/min subgroup. The NRI values suggest that the CKD-EPI cyst 
and CKD-EPIcreatcyst equations predict renal death and severe cardiovascular events more 
accurately than the other equations assessed. The BIS equation less accurately predicts renal 
deaths. 
Other literature 
The CKD-EPIcyst, CKD-EPIcreatcyst and BIS equations are new. Consequently, only 
limited data exist regarding the use of these equations to determine the prevalence of CKD in 
older individuals. In the BIS validation study (individuals aged 70 years and older) [7], the 
mean eGFR of the study population was 8 and 10 mL/min higher when estimated by the 
CKD-EPI and MDRD equations, respectively, than when estimated by the BIS equation. In 
our study (individuals aged 80 years and older), this difference in mean eGFR was 13 
mL/min (CKD-EPIcreat versus BIS) and 16 mL/min (MDRD versus BIS). Therefore, the 
mean difference in the mean eGFR obtained using these different equations appears to 
increase with age. To the best of our knowledge, no comparable data regarding the NRIs 
derived from the various GFR-estimating equations used in this article in older individuals 
have been reported. 
It is not surprising that differences are observed since some of these equations use serum 
creatinine, others cystatin C, and some both to calculate the GFR. Creatinine is a breakdown 
product of creatinine phosphate in muscles. The generation of creatinine depends on the 
muscle mass, which probably explains racial, ethnic, sex- and age-related variation in the 
generation of creatinine. Creatinine is a breakdown product of meat, so dietary intake of meat 
is another source of variation in serum levels of creatinine. Thus, the serum level of 
creatinine is influenced by more than just the GFR. Cystatin C is a protein produced by all 
human cells with a nucleus. The generation of cystatin C is thought to be less variable than 
creatinine in and among individuals, but there is evidence that factors other than the GFR, 
like smoking, body mass index, inflammation, corticosteroid use, proteinuria, diabetes and 
race, have an influence on the cystatin C level. Cystatin C is also an better predictor than 
creatinine of cardiovascular events [14]. 
One of the main conclusions of our study is that an eGFR <30 mL/min is always related to a 
large increase in the risk of negative outcomes, such as mortality and hospitalization. This 
result is independent of the GFR-estimating equation used. It is less clear whether older 
individuals with an eGFR between 30 and 60 mL/min are all at increased risk for adverse 
outcomes. Previous studies regarding the risk for negative outcomes in subgroups of older 
individuals with eGFR values between 45 and 60 mL/min yielded contradictory results. Some 
studies [1,15] reported an increase in mortality, whereas other studies [2,16] reported a clear 
increase in mortality only when the eGFR was lower than 45 mL/min. These discrepancies 
may result from differences in the GFR-estimating equation used or differences in the study 
population. The latter explanation is especially likely because older individuals with CKD 
have lower relative risks for negative outcomes than younger individuals at the same stage of 
CKD [17-19]. Notably, in this context, the eGFR not only decreases over time but often also 
increases [17,18]. 
Another finding was the U-shaped relationship between the CKD-EPIcyst equation and 
mortality and cardiovascular events. The finding that people with higher eGFR values 
calculated based on cystatin C have more events needs to be researched further. 
Given the high frequency of CKD in older individuals, it is important for physicians to 
distinguish between older patients with CKD who are at low risk for negative outcomes and 
older patients with CKD who are at high risk for negative outcomes. Various risk factors 
have been proposed for use in such a risk score, including the well-documented combination 
of eGFR and albuminuria [20-22], as well as the decrease in eGFR over time [23,24]. 
Strengths and limitations 
The main strength of our study is that the data originated from a population-based, 
prospective cohort study that has been demonstrated to be representative of the Belgian 
population [8]. Another strength is the employment of the correct standardization procedures 
for both creatinine and cystatin C. Furthermore, in addition to mortality and RRT, other 
relevant outcomes are reported, including hospitalizations, severe cardiovascular events and 
the probability of experiencing no events during a three-year period. The most important 
limitations of this study are the absence of a reference standard for measuring the true GFR 
and the measurement of albuminuria at baseline. 
Finally, the eGFR cutoff value of 60 mL/min used to define CKD in older persons in this 
study is often debated since a part of the decline in renal function with aging could be due to 
physiological changes. However, there are many arguments for a decline in eGFR as a 
pathological process in most patients [25] and the internationally accepted eGFR cutoff to 
define CKD was used in this study. 
Conclusions 
For octogenarians, a much higher prevalence of CKD and severe CKD was found when using 
the CKD-EPIcyst, CKD-EPIcreatcyst and BIS equations compared with the MDRD and 
CKD-EPIcreat equations. The CKD-EPI creatinine equation performed similarly to the 
MDRD equation in predicting adverse outcomes. The new CKD-EPIcreatcyst and CKD-
EPIcyst equations appeared to better predict mortality or RRT and severe cardiovascular 
events. By contrast, the new BIS equation was less accurate at predicting mortality and RRT 
compared with the MDRD equation. 
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